Supplements

Low-sodium oxybate reduces excessive daytime sleepiness and improves nighttime sleep quality in participants with narcolepsy

In a phase 4 open-label study of 34 participants with narcolepsy (NT1 or NT2), low-sodium oxybate (LXB) significantly reduced daytime sleepiness, with a least-squares mean change in Epworth Sleepiness Scale score of -7.7 (SE 0.9, P<0.0001). LXB also decreased transitions to lighter sleep stages by 13.1 (SE 2.9, P<0.0001), increased N3 (deep sleep) duration by 45.0 minutes (SE 8.8, P<0.0001), and reduced nocturnal awakenings by 3.2 (SE 0.9, P=0.0013). Most participants reported improved sleep quality and overall disease severity.

Last updated: Aug 26, 2026•0 RCTs•📖 Read as article →

Evidence Score

Evidence Score34/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study.

observational

Schneider LD, Ruoff CM, Plante DT, Nichols DA, Steininger TL, Fuller DS, Kirby MT, Akerman S, Alexander JK, Whalen M, Cairns A · Neurology and therapy (2026)

Participants: N/A
Duration: 5-12 weeks (2-8 week titration + 2-week stable dose)
Intervention: Low-sodium oxybate (LXB; Xywav) with dose titration over 2-8 weeks followed by a 2-week stable-dose period
Outcome: Epworth Sleepiness Scale (ESS) score, nocturnal polysomnography measures (transitions to lighter sleep, N3 duration, nocturnal awakenings), Narcolepsy Severity Scale (NSS/NSS-2), Patient Global Impression of Severity and Change, sleep quality eDiaries, cataplexy attacks (NT1 only)
Effect Size: ESS change: -7.7 (SE 0.9); N3 duration increase: 45.0 min (SE 8.8); nocturnal awakenings decrease: -3.2 (SE 0.9); NSS change (NT1): -19.7 (SE 2.7); NSS-2 change (NT2): -11.3 (SE 1.6)
Population: Participants with narcolepsy type 1 (NT1, n=16) or type 2 (NT2, n=18) who completed the study (total n=34)

Result:

PubMed: 42060037DOI: 10.1007/s40120-026-00921-3

Mechanism Graph

LXB contains calcium, magnesium, potassium, and sodium oxybates
↓
Oxybate acts on GABA-B receptors to promote slow-wave sleep
↓
Reduces transitions to lighter sleep stages and nocturnal awakenings
↓
Result: Increased deep sleep duration and reduced daytime sleepiness

Limitations

  • ⚠Open-label design without placebo control limits causal inference
  • ⚠Small sample size (n=34 completers) reduces generalizability
  • ⚠Short treatment duration (5-12 weeks) does not assess long-term efficacy or safety

Frequently Asked Questions

What is low-sodium oxybate (LXB) used for?▼

LXB (Xywav) is approved for treating excessive daytime sleepiness or cataplexy in people aged 7 years and older with narcolepsy, and for idiopathic hypersomnia in adults.

How was the effectiveness of LXB measured in the DUET study?▼

Effectiveness was measured using the Epworth Sleepiness Scale (ESS), nocturnal polysomnography (PSG), Narcolepsy Severity Scale (NSS/NSS-2), Patient Global Impression of Severity and Change, and daily eDiaries for sleep quality and cataplexy.

What were the main side effects of LXB in this study?▼

The most common treatment-emergent adverse events were nausea, dizziness, headache, drowsiness, and vomiting, consistent with the known safety profile of LXB.

Did LXB improve nighttime sleep in participants with narcolepsy?▼

Yes, LXB significantly increased deep sleep (N3) duration by about 45 minutes, reduced transitions to lighter sleep stages, and decreased nocturnal awakenings.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Schneider LD, Ruoff CM, Plante DT, Nichols DA, Steininger TL, Fuller DS, Kirby MT, Akerman S, Alexander JK, Whalen M, Cairns A. "Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study.." Neurology and therapy, 2026. PMID: 42060037 DOI: 10.1007/s40120-026-00921-3
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.